logo
About
R&D
Pipeline
Investors
News
Contact
For Patients
Primary Sclerosing Cholangitis
Nonalcoholic Steatohepatitis (NASH)
(NASH) דלקת כבד על רקע שומני
Investor Relations
Investor Relations
Overview
News & Events
News
Events
Presentations
Contact IR
Email Alerts
Financials & Filings
SEC Filings
Annual Reports
Quarterly Results
Stock
Stock Quote & Chart
Historical Stock Price
Analyst Coverage
Corporate Governance
Board Committees
Board of Directors
Leadership
Documents
News
Events
Presentations
Contact IR
Email Alerts
News
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Month Year
Su
Mo
Tu
We
Th
Fr
Sa
25
26
27
28
29
30
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
Cancel
Go
Email Alerts
Year
All Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Keywords
Go
Advanced Search
Search
Search Headlines Only
From
To
Asset Types
Photos
Video
Audio
Documents
Events
Standard
Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 29, 2023
Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate Update
August 14, 2023
Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis
June 28, 2023
Chemomab Therapeutics Presents Data Reinforcing the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2023
June 26, 2023
Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023
June 21, 2023
Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update
June 05, 2023
Patient Data Presented at 2023 EULAR Congress Highlights How Serum CCL24 Levels Can Predict Vascular and Fibrotic Complications of Systemic Sclerosis
June 02, 2023
Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
May 24, 2023
Chemomab Therapeutics Announces First Quarter 2023 Financial Results and Provides a Corporate Update
May 11, 2023
Chemomab Therapeutics to Present at 2023 Aegis Virtual Conference
April 26, 2023
Load More
Loading...